PacBio enables rare and inherited disease research by adding tertiary analysis partners to PacBio Compatible

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the addition of two tertiary analysis partners to PacBio Compatible. Geneyx and Golden Helix will enable PacBio customers to leverage PacBio HiFi data for disease research with the Revio and Sequel II/IIe sequencing systems.

Interpreting sequencing data generally involves primary, secondary, and tertiary analysis. Tertiary analysis powers knowledge discovery from variants, usually including annotation, filtering, and data visualization, and can provide further support for phasing and analyzing complex events such as structural variation. These new partnerships maximize value of HiFi data and complete the full end-to-end workflow for PacBio customers.

“Primary and secondary analysis solutions are available through our SMRT Analysis Software, the recently released PacBio WGS Variant Pipeline, and analysis partners such as GoogleHealth, all of which provide the best quality of data to power biological interpretation,” said Jeff Eidel, Chief Commercial Officer at PacBio. “Through our new partnerships with Geneyx and Golden Helix, researchers can accelerate their discoveries and find solutions from sample to answer across their HiFi-based workflows.”

Publications show that HiFi sequencing finds more structural variants (SVs) than short reads.1 SVs are important as they account for much of the genetic diversity between humans and have been shown to be associated with disease pathogenesis. Our tertiary analysis partners can further accelerate customers’ interpretation of this important variant class and enable PacBio customers to create a biological interpretation more easily from the underlying genomic content of their samples, maximizing the impact of PacBio sequencing on human health.

“Geneyx takes great pride in its partnership with PacBio. This collaboration leverages our HiFi sequencing data analysis expertise, enabling us to provide a comprehensive solution for long-read whole genome sequencing analysis. Our specialized tools, including phasing and methylation analysis, are tailored to PacBio data, simplify the bioinformatics process, and ensure accurate variant annotation and classification,” said David Yizhar, Chief Executive Officer of Geneyx. “Geneyx serves a diverse global user base, including PacBio customers. Together, our efforts will advance the realms of research.”

“Long-read sequencing has gained considerable popularity among our customers. Our clients are looking for reliable identification of rare variances, improved insights into challenging genomic regions, and top-notch calls for structural variants,” said Dr. Andreas Scherer, President and Chief Executive Officer of Golden Helix Inc. “We’re excited to collaborate with PacBio to offer a comprehensive solution to the market.”

PacBio Compatible works with a wide range of organizations to ensure customers can find verified products that are complementary to their workflows for PacBio sequencing. Partners collaborate closely with PacBio scientists to provide seamless integration and support for customers who are just starting out with PacBio or expanding their current capabilities. 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PacBio. (2023, November 01). PacBio enables rare and inherited disease research by adding tertiary analysis partners to PacBio Compatible. News-Medical. Retrieved on June 19, 2024 from https://www.news-medical.net/news/20231101/PacBio-enables-rare-and-inherited-disease-research-by-adding-tertiary-analysis-partners-to-PacBio-Compatible.aspx.

  • MLA

    PacBio. "PacBio enables rare and inherited disease research by adding tertiary analysis partners to PacBio Compatible". News-Medical. 19 June 2024. <https://www.news-medical.net/news/20231101/PacBio-enables-rare-and-inherited-disease-research-by-adding-tertiary-analysis-partners-to-PacBio-Compatible.aspx>.

  • Chicago

    PacBio. "PacBio enables rare and inherited disease research by adding tertiary analysis partners to PacBio Compatible". News-Medical. https://www.news-medical.net/news/20231101/PacBio-enables-rare-and-inherited-disease-research-by-adding-tertiary-analysis-partners-to-PacBio-Compatible.aspx. (accessed June 19, 2024).

  • Harvard

    PacBio. 2023. PacBio enables rare and inherited disease research by adding tertiary analysis partners to PacBio Compatible. News-Medical, viewed 19 June 2024, https://www.news-medical.net/news/20231101/PacBio-enables-rare-and-inherited-disease-research-by-adding-tertiary-analysis-partners-to-PacBio-Compatible.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.